FILE - A sign for the Food and Drug Administration is seen in Silver Spring, Md., on Thursday, Dec. 10, 2020. On Wednesday, March 30, 2022, federal health advisers narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease, a potential setback for patient groups who lobbied for the medication’s approval. A majority of advisers to the FDA voted 6-4 that a single study from Amylyx Pharmaceuticals failed to establish the drug's effectiveness in treating the deadly neurodegenerative disease known also as ALS, for amyotrophic lateral sclerosis. (AP Photo/Manuel Balce Ceneta)
Featured Photo Galleries
